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Introduction
The association between elevated serum cholesterol and coronary heart disease (CHD) was ¢rst noted in the early 19th century, when cholesterol crystals were discovered in atherosclerotic plaques in coronary arteries. 1 The causal relationship between serum cholesterol and atherosclerosis remained speculative until the 1950s, despite experimental and clinical evidence. The invention of the ultracentrifuge 2 led to a greater understanding of lipoprotein metabolism, which was based previously on electrophoretic patterns. 3 In the 1960s and 1970s, with epidemiological methods still in their infancy and with very few clinical trials, clinicians remained resistant to the general idea that increased serum cholesterol was associated with CHD. However, data began to appear outlining the basis of a genetic disorder of cholesterol metabolism that was associated with premature CHD and had characteristic clinical features. This disorder, whose clinical features were probably ¢rst described in 1900, 4 was familial hypercholesterolaemia (FH). Between the 1930s and 1950s, several investigators recognized the genetic aspects of FH, 5,6 and studies indicated that a cholesterol-carrying particle called LDL was increased. In the late 1970s, Goldstein and Brown 7 discovered a receptor for LDL on the cell surface and demonstrated that it was a mutation in the LDL receptor gene that caused the clinical syndrome of FH. 8, 9 The term FH is used to describe an inherited disorder of lipoprotein metabolism, characterized by elevated LDL cholesterol, tendon xanthomata and risk of premature CHD. It is distinct from simple heritable conditions that lead to increased serum cholesterol. Hypercholesterolaemia in FH is present from birth. The original de¢nition stated that FH arose from a defect in the LDL receptor gene. FH is, therefore, an example of a monogenic disorder that results from a speci¢c mutation in a single gene. However, it is now recognized that there are other single gene mutations associated with hypercholesterolaemia that can produce a clinical phenotype similar to FH (Table 1) .
Characteristic clinical features of FH
Variation in the clinical phenotype in FH is not uncommon, and not surprisingly, the phenotype is a¡ected by environmental, metabolic and other genetic factors (see later). Two clinical forms are recognized, namely heterozygous FH and homozygous FH. The presence of tendon xanthomata and premature CHD appearing in the third or fourth decade of life are pathognomonic of patients with heterozygous FH. In the patients with homozygous FH, or those who are compound heterozygotes, tendon xanthomata are present, but other additional features include cutaneous xanthomata and CHD that invariably appears before the age of 25 years.
There are several early descriptions of the characteristic cutaneous and tendon xanthomata seen in FH, 16--18 but Burns 4 provided one of the ¢rst complete descriptions of classical FH. Further reports on two series of patients in the 1930s by Muller 5 and Thannhauser 6 con¢rmed that FH was associated with premature CHD.
Tendon xanthomata typically appear in extensor tendons. They are commonly found in Achilles tendons and extensor tendons on the dorsum of the hands, and rarely in the triceps tendons and over the tibial tuberosity. Sometimes they may not be palpable, but simply detected as thickening of the tendons. Both xanthomata and thickening can be unilateral, with the Achilles tendon being the most common site. Achilles tendinitis is frequently encountered in FH, especially in patients with ill-¢tting shoes, or in those who are physically active with sports shoes impinging on the tendons. 19, 20 Patients have presented with rupture of the Achilles tendon or unknowingly have tendon xanthomata removed, only to ¢nd the pathological specimen full of cholesterol. 21 In such cases, the Achilles tendons are markedly weakened.
The age at which tendon xanthomata are ¢rst clinically detectable is variable and may vary according to the mutation present or degree of hypercholesterolaemia. Undoubtedly, they become more apparent with increasing age. In one series, nearly 70% of patients had tendon xanthomata by the age of 30. 22 There is some evidence of a relationship between tendon xanthomata, and the onset or severity of CHD. 23 Ultrasound, 24 computerized tomographic scanning 25 and magnetic resonance imaging 26, 27 can identify tendon xanthomata that may not be clinically apparent, but these are rarely used in routine clinical practice. Tendon xanthomas can regress with cholesterol-lowering treatment, although it is rare for them to disappear completely. With increased awareness of raised serum cholesterol as a risk factor for CHD, patients with FH are frequently prescribed cholesterollowering drugs without being examined for the presence of tendon xanthomata, thereby making the clinical diagnosis of FH di⁄cult. Patients with homozygous FH are rare, and tendon xanthomata in these patients appear much earlier, often in childhood, and also at atypical sites such as the triceps and pre-tibial tendons.
Cutaneous xanthomata are yellow--orange planar cutaneous lesions that occur exclusively in patients with homozygous FH and appear in the ¢rst or second years of life, typically on the knees, elbows, buttocks and the dorsum of the hands. Tuberous xanthomata can also be seen in the same sites as planar xanthomata.
Other clinical features seen in patients with FH
Probably the most common non-speci¢c feature seen in FH is the corneal arcus. If it appears prematurely (as distinct from arcus senilis), it almost always indicates a genetic disorder of cholesterol metabolism or premature CHD. Corneal arcus tends to appear in the mid--to--late thirties in patients with FH. The initial lesion is a superior corneal arcus, followed by an inferior arcus, and in the later stages, a complete corneal arcus. The pathophysiology is unclear, may be related to £uctuations in corneal temperature. 28 Xanthelasmata are also non-speci¢c, but are encountered frequently in FH. Typically, they occur on the outer surface of the upper eyelid, and/or in the lower eyelid and sometimes extend to the medial aspects of both eyes. They are often bilateral and are frequently removed for cosmetic reasons. Aortic stenosis frequently occurs in patients with heterozygous FH, and is always at presentation in patients with homozygous FH. 29 It occurs as a result of cholesterol deposits that occur on the aortic root and possibly on the aortic valve. The deposits can also be supravalvular and are detected as an aortic systolic murmur, which may radiate to the neck. There are also reports of cholesterol deposits on mitral valve cusps. 30 
Other disease associations
It is thought that hypertension, hypertriglyceridaemia or hyperuricaemia are uncommon in patients with FH. 31 The reason for this is not clear. Hypertension and hypertriglyceridaemia are also recognized features of familial combined hyperlipidaemia (familial combined hyperlipidaemia (FCH)) and, clinically, this di¡erence may help distinguish FH from FCH. 32 Type III or remnant hyperlipidaemia can coexist with FH. 33, 34 It is uncommon, but the reason or signi¢cance of this co-occurrence is not clear.
An association between joint pain and FH has been described. 35 Rheumatological manifestations include small and large joint arthropathy, and pain associated with tendinitis in the presence or absence of xanthomata. 36 These features are common in homozygotes but are also seen in heterozygous FH, and in some patients a rapid lowering of markedly elevated serum cholesterol levels can produce £itting small joint polyarthropathy that can last 7--10 days. Such episodes are seen frequently in homozygotes and are unrelated to cholesterol lowering treatment. 37, 38 Vascular disease in patients with FH Patients with heterozygous FH have premature CHD 39 and peripheral vascular disease. 40 The relationship between ischaemic stroke and FH is unclear, with most studies indicating no increased risk. 41 Patients with homozygous FH succumb to premature CHD much earlier than heterozygotes, and the symptoms generally appear during the teenage years or earlier. 42, 43 Despite aggressive management with LDL apheresis and prophylactic coronary artery bypass grafting, the prog-nosis remains poor. Sudden death also seems common in homozygotes, and may account for many undetected cases.
The nature and onset of CHD in heterozygotes is much more variable. 44 The widespread use of statins and the laudable emphasis on the early detection and treatment of coronary risk factors makes it more di⁄cult to establish the natural history of CHD in heterozygous FH. There is some indication of the natural history of CHD in FH from previous studies carried out in the USA, 45 UK, 46 Scandinavia, 47, 48 Canada, 49 France, 50 Holland 51 and Japan. 52 However, not all studies were well designed, and many of the patients were on lipid-lowering drugs (although not the more powerful statins) making interpretation and/or comparison of data di⁄cult. Austin et al. 39 have summarized the association between FH and CHD.
There have been attempts to correlate the severity of CHD and speci¢c mutations leading to the FH clinical phenotype, 53--55 but the numbers of patients examined have generally been small, and the di⁄culty is compounded by the large allelic variation. Furthermore, the de¢nition of CHD also varies between the studies, and the geographical prevalence of CHD will also in£uence the disease in patients with FH. 56--58 Data examining allele-speci¢c associations by grouping mutations from di¡erent areas in non-founder populations, or by studying the e¡ects of mutations in founder populations, or by geographic location of mutations, 39 would suggest that receptor-negative mutations may lead to more severe CHD compared with receptor-defective mutations.
Biochemical features of FH
The characteristic biochemical feature of FH is hypercholesterolaemia. This results from an increase in the lipoprotein fraction over the density range from 1.006 to 1.063 g/mL. This fraction predominantly contains LDL, but the operational de¢nition also includes intermediate-density lipoproteins. LDL particles are increased in number, and the long residence time also alters their composition, leading to a decrease in triglyceride content, with increases in cholesterol and phospholipids. 59 The protein content remains unaltered. The increase in LDL concentration and particle number are clearly due to decreased catabolism due to an LDL receptor defect, but there is some evidence to suggest that there is also overproduction of LDL. It is unclear whether this overproduction is due to a decreased catabolism of intermediate-density lipoproteins (IDL), which is then converted to LDL, or is a result of direct increase in LDL production from the liver. 60 HDL levels are generally decreased in FH patients. 61 Lipoprotein (a) levels are increased in patients with FH, 62--64 but it is unclear whether this a¡ects the prevalence of CHD.
The genetic basis of FH
FH results from a defect in the LDL receptor gene. This gene is situated on the short arm of chromosome 19, has 18 exons and stretches over 45 kb. 65, 66 Its product, the LDL receptor protein, is responsible for removing LDL from plasma. 67 FH was initially thought to be due to a defect of cholesterol synthesis, but analytical ultracentrifugation studies in the 1950s suggested that the increased cholesterol in FH was due to an increase in LDL. This was further con¢rmed in the 1960s by Fredrickson who demonstrated impaired LDL metabolism. 68 Further studies in the1970s showed a decreased fractional catabolic rate of LDL. 69 Brown and Goldstein 70 furthered this ¢nding by carrying out studies on ¢broblasts cultured from healthy subjects and patients with homozygous FH. Their work led to the discovery of the LDL receptor and demonstrated its absence in patients with homozygous FH. 71 In the late 1970s, genetic linkage between C3 (complement) located on chromosome 19 and clinical FH was described. 72 Brown and Goldstein 73 then went on to identify the LDL receptor gene and showed that FH was caused by mutations in this gene.
Classical FH is an autosomal co-dominant disorder, which a¡ects men and women equally, and has almost complete penetrance. More than 800 mutations have been described worldwide, although there is some suggestion that FH appears to be more common in those of white European descent. A description of these mutations is available online. 10 A detailed review of genetic causes of FH has recently been published, and is also available on the Human Genome Epidemiology network. 43 Most mutations are seen in exon 4, but variants occur along all 18 exons and in the promoter region. Some 5% of mutations consist of deletion or duplications and are found in exons 1--18 and intron 12. It is possible to classify the mutations on the basis of their disturbance in function due to the abnormal protein produced (Table 2) . This classi¢cation helps with the understanding of LDL receptor physiology, but can be misleading as mutations may fall into two or more functional classes. Class 1 mutations are null alleles with no protein synthesis and generally result in a severe clinical phenotype. Some mutations in exon 4 are also associated with a severe phenotype. There is a marked geographical variation of the mutations, except in founder populations (populations who have a common gene pool and who have been genetically relatively isolated), such as in the Afrikaans, French Canadians,Tunisians, Lebanese, Danish, Japanese and North Koreans. 39 A variety of other genes that are linked with the clinical phenotype of FH have recently been identi¢ed (Table 1) . Notable among these is familial defective apolipoprotein B (FDB). 74 This condition results from a mutation in apolipoprotein B, the ligand for the LDL receptor, which itself is normal.
The basis of phenotypic variability in FH
As more studies on FH are reported from di¡erent geographical locations, it has become apparent that there is considerable variability in the expression of the FH phenotype. 75 Not all the classical features of FH originally described are present in all patients, including the pre-treatment serum cholesterol level, the presence of tendon xanthomata, the presence of non-speci¢c features of hyperlipidaemia such as premature corneal arcus and xanthelasmata, the onset and severity of coronary artery disease, the e¡ect of gender on phenotype variability and the relationship between the degree of hypercholesterolaemia and CHD.
Genetic, metabolic and environmental factors can all in£uence the phenotypic variability (Table 3) , but the numbers studied to establish these data are small and derived mainly from case--control studies. 76--80 A family history of premature CHD in patients with FH is an example of a genetic factor that contributes to phenotypic variability, which can be of practical utility in coronary risk assessment in the clinic. 81 82 However, there is a degree of familial clustering with patients from the same family presenting with similar serum cholesterol levels. The precise reason for this has not been investigated. Studies in the Afrikaners 83 and French Canadians 84 suggest that certain mutations are associated with a more severe phenotype. Studies from other countries without founder populations also suggest that certain LDL receptor defects can be associated with a 'severe' or 'mild' phenotype. 85--89 Most of the studies have been carried out on European populations, and attempts have been made to 'pool mutations' to determine the e¡ect on phenotypic variability. Results vary, but generally receptor-negative mutations are associated with a more severe phenotype, compared with receptor-defective mutations. Given the ethnic heterogeneity and possible selection bias, it would be di⁄cult to apply ¢ndings universally. Similar limitations apply to data derived from studies on patients who were homozygotes or compound heterozygotes.
Factors influencing the FH phenotype Genetic
Genes that in£uence the assembly or secretion of lipoproteins or are responsible for their remodelling can also a¡ect the FH phenotype.When type III hyperlipidaemia coexists with FH, patients tend to have hypertriglyceridaemia and lower LDL cholesterol levels 33, 34 and are prone to early CHD and peripheral vascular disease. However, the e¡ect of apolipoprotein E genotype on the FH phenotype seems to vary with the population examined. 90, 91 It is unclear whether the other apolipoprotein E genotypes in£uence FH, over and above the e¡ects on LDL cholesterol seen in the non-FH population.
Patients with lipoprotein lipase de¢ciency have pronounced hypertriglyceridaemia and low HDL choles-terol levels. The mutations causing the enzyme de¢ciency generally do not confer an increased risk of CHD, but when occurring in the presence of FH, there are reports of increased cardiovascular risk, although in another report LDL levels were quite low. 92, 93 The e¡ect of other genetic factors such as cholesteryl ester transfer protein (CETP), 94, 95 microsomal triglyceride transfer protein (MTP), 96 hepatic lipase, fatty acid-binding protein, 97 methylene tetrahydrofolate reductase (MTHFR), 98 ATP-binding cassette A1 (ABCA1), 99 renin--angiotensin 100 and paraoxonase 101, 102 have been described, but it would seem that it is rare for them to exert a major in£uence on the FH phenotype. Gender does seem to have a major in£uence on the FH phenotype, 77 with women demonstrating clinical features of CHD later than men, but earlier than women without FH.
Metabolic
The expression of LDL receptors is in£uenced by many factors, and it would, therefore, be expected that they would also in£uence the FH phenotype. Physiological, pathological or pharmacological variation in thyroid hormone 103 or oestrogen 104 levels can a¡ect the FH phenotype. Similarly, prolonged fasting or dieting for weight loss can also in£uence LDL cholesterol levels in FH, 77 possibly by decreasing availability of substrate for lipoprotyein synthesis. Lipoprotein (a) is increased in FH. It has been established that increased lipoprotein(a) is a risk factor for CHD, particularly in the presence of increased LDL cholesterol; however, its role in increasing CHD risk in FH is unclear. 105 LDL particle size is associated with increased CHD risk in FH, 106 as is a low HDL cholesterol. 107 Remnant-like proteins are increased in FH 108 and may lead to increased CHD in patients. Increased plasma ¢brinogen, C-reactive protein and homocysteine have all been associated with increased risk in the non-FH population, but their role in increasing CHD risk in FH is undetermined. 109 
Environmental
The two most characteristic features of FH, increased LDL cholesterol and premature CHD, are also signi¢cantly in£uenced by environmental factors. 110 Dietary, behavioural and cultural factors will inevitably a¡ect the FH phenotype, as will the prevalence of CHD in the community or country of origin. Some elegant studies from Holland suggest that CHD is more common in FH presently than in the previous century. 111 Heterozygotes for FH in China 112 and Cuba, 113 countries with a low prevalence of CHD, also have lower LDL cholesterol levels and less CHD compared with those in the industrialized West. 111 Physicians are increasingly treating hypercholesterolaemia at an earlier stage, often without establishing its origin or nature. Thus, treatment commonly modi-¢es the FH phenotype. Early treatment with cholesterol-lowering drugs may prevent the appearance of tendon xanthomata, and only those patients with a mutation resulting in very high serum cholesterol values may be detected as being 'resistant' to treatment. Cholesterol-lowering treatment will also decrease the chance of premature CHD, but there are data to suggest that the LDL receptor defect itself can cause premature CHD regardless of serum cholesterol levels. 114, 115 Screening strategies for FH The Wilson and Jungner criteria, originally proposed in 1968, 117 are the guiding principles for introduction of screening. There is now also a thrust to base screening programmes on high-quality randomized controlled trials with an agreed set of quality assurance standards for managing and monitoring the screening programme. 118 However, in practice, screening is often driven by patients, their relatives and patient organizations, interested clinicians or the availability of a new test. Inevitably the psychological and economic issues come to the fore, raising issues about ethics and logistics of screening as well as the need for resources and the capacity to manage and treat new cases detected by screening. The sensitivity and speci¢city of a test are no doubt important, but it is also important to understand how clinicians will use a particular test and make clinical decisions.
FH ful¢ls the Wilson and Jungner criteria for screening, but, as yet, very few countries have a screening programme for the condition. 119 Its prevalence is low compared with other lipid-related coronary risk factors, making the population at risk much smaller. However, the relative odds of developing CHD are the highest compared with common hypercholesterolaemia. 31 All current guidelines used in the Western world advocate the screening of individuals with a high risk of premature CHD based on strong family history, and FH would certainly be included in this category. 120 A lack of resources and public health priorities has resulted in a relative lack of interest in a programme for screening for FH. The wide variety of mutations and phenotypic variability has also made it di⁄cult to establish de¢nite diagnostic criteria. Three groups in three di¡erent countries have put forward their own diagnostic criteria for FH based on experience with large cohorts. The Simon Broome Register criteria were put forward in 1991 in the UK (Table 4) 121 and included cholesterol levels, clinical features, family history and also accommodated a molecular diagnosis. In contrast, the US MEDPED criteria, 122 published in 1993, were based on serum cholesterol cut-o¡ points in di¡erent age groups, based on whether they had ¢rstand second-or third-degree relatives with FH (Table 5 ). The criteria were derived from modelling known serum cholesterol levels in patients with FH in the USA and Japan, and their comparison with the general population. The Dutch Lipid Clinic Networks criteria for FH were published in 1999. 123 Like the Simon Broome Register criteria, they include family and Table 4 Simon Broome Familial Hypercholesterolemia Register diagnostic criteria for familial hypercholesterolaemia
Criteria Description
A Total cholesterol concentration above 7.5 mmol/L in adults or a total cholesterol concentration above 6.7 mmol/L in children aged less than 16 years, or LDL cholesterol concentration above 4.9 mmol/L in adults or above 4.0 mmol/L in children B
Tendinous xanthomata in the patient or a first-degree relative C DNA-based evidence of mutation in the LDL receptor or apoB gene D Family history of myocardial infarction before age 50 years in a second-degree relative or before age 60 years in a first-degree relative E Family history of raised total cholesterol concentration above 7.5 mmol/L in a first-or second-degree relative clinical history, clinical features, cholesterol levels and mutation analysis, but each criterion is given a weighting (Table 6) . Given the hypercholesterolaemia, a personal or family history of premature CHD and tracking of hypercholesterolaemia in ¢rst-degree relatives, it should be possible to screen patients clinically and by mutation testing either individually, or in combination. 
Diagnosis

A 'definite' FH diagnosis requires either criteria A and B or criterion C A 'probable' FH diagnosis requires either criteria A and D or criteria A and E
Population screening
Universal screening is feasible, 124,125, but is unlikely to be cost-e¡ective even in founder populations where the prevalence of FH is high. No such programmes have been described. Whether universal screening of all children will be more cost-e¡ective is unclear.
Screening in the clinical setting
Most patients with FH have pure hypercholesterolaemia. The serum triglycerides are rarely increased, unless there are other causes. The index of suspicion should be high in patients who have serum cholesterol values greater than 8 mmol/L. In the UK, it is unusual to see serum cholesterol concentrations that are greater than 7 mmol/L wholly as a result of a diet high in saturated fat. Secondary causes of hyperlipidaemia such as thyroid, liver or renal function should be excluded. These disorders are often apparent on history taking and/or revealed by speci¢c tests. A personal, social and occupational history will provide further evidence of lifestyle factors that lead to a poor diet. There may be a previous history of hypercholesterolaemia that may have simply been treated by diet. Not all patients with FH have clinical signs (especially those on treatment), which are, in any case, rarely seen in patients below the age of 30 years. The presence of corneal arcus and/or xanthelasmata, particularly in association with hypercholesterolaemia, is suggestive of a genetic disorder of lipoprotein metabolism. Tendon xanthomata are, of course, the pathognomonic sign. It is always worthwhile listening for the murmur of aortic stenosis.
The other disorders that need to be distinguished from FH are familial combined hyperlipidaemia (FCH), type III or remnant hyperlipidaemia, secondary hyperlipidaemia due an obstructive liver disorder and sitosterolaemia. In FCH, there is often a strong family history of hyperlipidaemia and premature CHD, but no tendon xanthomata. 126 In untreated patients with type III hyperlipidaemia, palmar crease xanthomata and eruptive xanthomata on pressure points can occur, and, rarely, tendon xanthomata. Both these disorders can also be associated with corneal arcus and xanthelasmata. The characteristic mixed hyperlipidaemia seen in FCH and type III hyperlipidaemia can help distinguish the disorders from the pure hypercholesterolaemia seen in FH. However, obesity and excess alcohol consumption can induce hypertriglyceridaemia in FH patients. Patients with biliary obstruction have pure hypercholesterolaemia and often £orid xanthelasmata, but they also have jaundice, which together with increases in alkaline phosphatase and GGT activities point to liver disease. Sitosterolaemia is a very rare disorder due to mutations in the ATP-binding cassette transporters ABCG5 and ABCG8. 15 Many patients have hypercholesterolaemia, although often the parents have normal cholesterol concentrations.
It is thus possible to arrive at a clinical diagnosis of FH either by exclusion of other disorders or by a combination of clinical signs and personal and family history, but the yield of new patients is likely to be low with opportunistic screening in the clinic. However, it is always worthwhile making an e¡ort to document the clinical diagnosis as de¢nite, probable or possible FH based on the Simon Broome criteria (Table 4) or the cholesterol cut-o¡ points in the US system (Table 5) or the points--based system used by the Dutch (Table 6) .
Screening for FH in patients with premature CHD is likely to yield larger number of patients with FH than opportunistic screening; but disorders other than FH and certain polymorphisms will also account for premature CHD. It will also not overcome the issue of the link between risk factors such as increased serum cholesterol in non-FH patients and CHD seen due to familial aggregation of CHD.
Screening relatives of FH probands
This approach is also termed cascade testing or family tracing 127 and can be achieved by testing serum cholesterol concentrations or by genetic testing. This method of identifying FH has been tried in several settings in the UK, 128 Holland, 129, 130 Norway, 131 Iceland 132 and the USA. 122 One group from the UK 128 were able to ¢nd 121 new patients from a register of 262 probands using cascade testing and determining serum cholesterol in 200 relatives of the 262 probands. In contrast, if the prevalence of FH is assumed to be one in 500, universal screening of 60,000 tests would have to be carried out to detect a similar number of patients. It is of interest is note that, while about 90% of probands had tendon xanthomata, only about 25% of relatives had this diagnostic sign.
Most cascade testing is ideally carried out in specialist centres such as lipid or cardiovascular risk management or metabolic clinics; clinics run by nurses trained in genetic counselling and cardiovascular risk management are ideal for this purpose.
Before cascade testing is undertaken via identi¢cation of probands as FH, the need for clinic space and family mapping software and the necessary capacity and resources for follow-up of newly discovered patients, including children, is an important consideration. Funding varies with health-care systems worldwide, and it is important that a formal recognized programme for cascade testing is in place instead of ad hoc or sporadic testing.
One of the main issues with cascade testing is the de¢nition of FH in a clinical setting. Genetic testing for diagnosis is virtually unavailable in most places due to high cost, or is fraught due to di⁄culties relating to a lack of access. In addition, some clinicians often use the term 'familial' in a loose or colloquial way to describe patients who have a family history of elevated serum cholesterol. This diagnosis then gets perpetuated in the case notes. It is best to make an attempt to characterize the diagnosis as de¢nite FH or probable or possible FH, based on the clinical criteria described earlier or when the genotype is known. Patients in the former two categories should de¢nitely have family tracking.
Probands and their relatives should be approached with great sensitivity in order to minimize the anxieties that can be associated with screening. 133 Some young relatives prefer to have testing for the diagnosis of FH delayed, while others remain in a 'state of denial' and prefer not to be tested at all. 134, 135 Screening also has the potential to lead to family discord, especially when children are asked by parents to avoid certain foods. The person conducting cascade testing should also be aware that there is debate about whether the probands should invite the relatives for testing or should provide the names of the relatives so that the screening programme can approach them for testing. 136 This may well have a cultural context. For example, in Denmark, it is ethical to approach a relative directly, but this is not the case in the Netherlands or many parts of the UK. 137, 138 It is, however, reassuring to note that most studies show that the psychological e¡ects of screening among relatives of probands are no greater than that seen in the general population. 139--142 Relatives should also be advised before screening that, if they are found to have FH, their insurance premiums are likely to increase. 143--145 The insurance industry is being made aware that genetic testing or testing for genetic disorders should not be treated as a special case. 146, 147 Even more problematic is the diagnosis of FH in relatives. In addition to the ¢rmness of the diagnosis in the proband, the age at which the relative is tested, lifestyle issues, the serum cholesterol cut-o¡ points used for diagnosis and the country where cascade testing is being carried out will all have an impact on the ability to diagnose FH.
Cascade testing using clinical criteria
There are no ¢rm data on the sensitivity and speci¢city of the di¡erent criteria used for screening for FH. A study from Denmark compared the Simon Broome, Dutch and MEDPED criteria in a group of 408 probands with a known FH mutation. 148 The speci¢city for the presence of a mutation reached 90% in the de¢nite group, but was lower for the possible and probable categories de¢ned by both the Simon Broome and Dutch criteria. All three sets of FH criteria had a low sensitivity (proportion of mutation-positive diagnosis) with ¢gures varying between 34 and 42% in de¢nite FH, but high (490%) in possible or probable FH. Overall, the study suggested that around 60% of de¢nite FH patients would be found to be mutation positive by the UK and Dutch criteria, but only 36% when possible FH patients were included in the sample. The main drawback here is that, in some patients who had FH clinically, the mutation may be unknown.
Cascade testing using genetic testing
There is bound to be a degree of uncertainty when clinically-based criteria are used in cascade testing; 149 but it is unclear if genetic testing of relatives of probands with FH will be a better option. Genetic testing can be an emotive issue with the lay public, but patients, on the other hand, are often more pragmatic. 150 Either way, it is important to deal with the information gathered from genetic testing through appropriate counselling and by explaining the impact of the diagnosis and the bene¢ts of treatment. 151 While many clinicians will equate genetic testing and clinical criteria as just another way of arriving at a diagnosis, for patients the nature of genetic tests is such that it is necessarily seen as extending into the family. In one study using genetic screening for cascade testing of relatives of patients with haemochromatosis, the uptake was poor, but improved dramatically when accompanied by skilled counselling. 152 In another population-based study of screening for haemochromatosis, 3000 subjects were randomized to a phenotype blood test or a genotype saliva test. 153 The overall uptake was poor, but acceptance of genetic testing was no di¡erent to transferrin saturation tests. The poor uptake in this population-based study is probably a case for restricting testing in families to those at high risk of developing disease, as the bene¢ts of screening would greatly diminish with a lack of participation of those at risk. 154 There have been several studies using mutation testing to detect FH, but the allelic heterogeneity 10,155 and the other genetic in£uences and environmental e¡ects decrease the utility of genetic testing. Moreover, any approach to screening will probably need to be country or community speci¢c. New techniques or a combination of existing molecular biology methods may overcome some of the technical hurdles, 156--159 but this will not ameliorate the issue of the lack of detection of a mutation in someone in whom the clinical type is not suggestive of FH. The current techniques are relatively insensitive in screening the whole LDL or apo B gene, and there are also likely to be genes responsible for FH which are yet to be discovered.
Genetic testing does have its advantages. It helps develop a genetic database of disease. 160 It can also provide new insights into disease mechanisms which can be obtained by correlating the genotype with the severity and environmental determinants of the phenotype, and also the response to treatment.
The Dutch have the greatest experience of genetic screening of relatives with FH with a screening programme that started in1994. 161 Of FH patients of Dutch origin, 80% are known to have 130 di¡erent LDL receptor mutations. It is limited by the fact that they only tested the relatives with those known to have a particular mutation. Interestingly, 10% of relatives declined to be tested. The programme is important because, to date, they have identi¢ed nearly 6000 new patients by this method, 162 which indicates that patients are being treated at an earlier age.
The Norwegian experience of cascade genetic testing detected 48% of new patients with FH. 132 Programmes for genetic screening are being developed in Spain 163 and have resulted in extensive guidelines for management of FH. 164 Studies in countries with smaller populations, such as Northern Ireland 157 and New Zealand, 165 have also led to de¢ned screening programmes. The Northern Ireland group reports a detection rate of 80% by genetic testing, 82 which was improved further by a method that included screening the non-coding intron splice region of the LDL receptor gene. The Icelandic approach suggests that screening all individuals genealogically traced to a common ancestor from a proband may be better than cascade testing. 131 This model is unlikely to be adopted outside Iceland as most populations are much more heterogeneous, and also due to the di¡erent ethical and public attitudes and the lack of a national whole population genetic database. In Denmark, ¢ve mutations account for 40--50% of patients with FH 166, 167 with the authors suggesting that genetic testing for FH be introduced in routine clinical practice.
The above studies indicate that cascade testing using genetic tests would identify between 60 and 80% of patients with de¢nite FH. The ¢gure in probable and possible FH is likely to be much poorer. It is possible that in the future, with more community-speci¢c programmes, newer, speci¢c batteries of gene chips may become available for testing. There are several further steps that need to be taken to move to service provision for genetic testing. The European Society of Human Genetics makes several recommendations 168--170 and lays down criteria such as patient choice, economic aspects and social aspects. It suggests testing the population at risk rather than universal screening. In the UK, genetic services, in general, are still being developed. 171 At present, in the UK, no programmes for genetic testing for FH exist outside research departments. As services develop, pro¢ciency testing of clinical genetic testing laboratories will become an important issue. 172, 173 A recent study from Italy 174 reported that nearly half of the laboratories using basic techniques of DNA extraction, polymerase chain reaction (PCR) and electrophoresis interpretation did not have acceptable results, prompting a call to change disease-gene-speci¢c quality assurance programmes. 175 Cost-effectiveness of cascade testing for FH Direct and indirect health-care costs, the extent of use of health-care resources, the consequences to the patient of testing and the e¡ect on clinical outcomes in patients will all determine the cost-e¡ectiveness of any screening programme. Studies from the USA indicate that identifying cholesterol results in patients leads to bene¢t from increased and appropriate use of statins. 176 Researchers from Holland, using genetic screening, also report similar bene¢ts of increased awareness of treatment, 177 although a di¡erent Dutch group reports that the risk of CHD remains high in patients with FH even after statin treatment. 178 The Dutch groups have also reported on the cost-e¡ectiveness of their programmes. 179, 180 The most detailed analysis of cost-e¡ectiveness of screening for FH is provided by Marks et al. 181 who evaluated models of universal screening, opportunistic screening in primary care, screening in patients with a recent myocardial infarction and family tracing of relatives of probands. 182 They conclude that cascade testing using clinical criteria was the most cost-e¡ective, followed closely by genetic cascade testing (Table 7) . Screening patients with myocardial infarction using clinical criteria, but not genetic testing, was three times the cost of clinical cascade testing. The modelling was based on many assumptions; however, it is likely that cost-e¡ectiveness for FH screening will improve with a fall in the cost of drugs for lipid lowering and, perhaps, in genetic testing.
In the UK, the Department of Health has funded a FH cascade testing project which is being coordinated by the London IDEAS Genetic Knowledge Park. 183 The aim of the project is to plan and oversee service delivery pilots for the cascade testing of relatives of patients with FH and determine the potential implications for the implementation of a national programme, including its resource and manpower implications. Specially trained nurses will initially audit lipid clinics in ¢ve conurbations in England for probands. This will be followed by cascade testing of relatives of probands with de¢nite, possible and probable FH using the Simon Broome criteria. The group has produced tables for diagnosing FH in relatives based on age and LDL cholesterol cut-o¡s derived from Bayesian analysis of genotype--phenotype correlations from the Dutch genetic cascading study. 183 Other attempts have also been made to produce cut-o¡ points for diagnosis, 184 but none are in common use.
Conclusion
There is always likely to be uncertainty in establishing the diagnosis of FH. This is particularly so with the worldwide geographical variability of the phenotype and the discovery of new mutations. Clinicians need to be made aware of the clinical features of FH that will raise their index of suspicion and of the potential impact of missing the diagnosis for the patient. In patients with hypercholesterolaemia, especially those referred to secondary care with apparent resistance to treatment, every attempt should be made to take a detailed personal and family history to establish if there is a genetic component to the hypercholesterolaemia or premature CHD. In fact, it is worth asking the question why a particular patient does not have FH or another genetic hyperlipidaemia until proven otherwise. In the absence of any clinical signs, a 'diagnosis of exclusion' is made where dietary causes and secondary hyperlipidaemia are excluded.Where a proband is known, it may be worthwhile looking for the particular mutation present in the family.Where the family history is of little help and the age of onset or pattern of hyperlipidaemia is suggestive of a genetic condition, then testing for common mutations may be feasible in certain countries. For the future, perhaps more work is needed in whole gene screening and family studies so that DNA testing and serum lipid estimations can be combined with the clinical picture of FH for the accurate diagnosis of relatives of probands. 
